Table 3.
Undiscounted results
| Scenario | Outcomes | Costs (€) per woman | ||||
| Cancer | Cancer mortality | OS organisation | Screening | CC care and conisations | Total | |
| IndScr only* | 34 | 13 | 0 | 294.2 | 30.9 | 325.0 |
| Pap/Pap | −14.2% | −13.5% | +19.57 | +13.32 | −3.92 | +28.97 |
| Pap/p16Ki67 | −16.6% | −15.9% | +19.57 | +18.46 | −4.57 | +33.46 |
| HPV/Pap-3y | −21.1% | −22.4% | +15.16 | +99.87 | −7.31 | +107.73 |
| HPV/Pap-5y | −18.9% | −22.5% | +15.12 | −29.79 | −7.24 | −21.91 |
| HPV/Pap-10y | −8.0% | −13.6% | +14.94 | −14.42 | −0.48 | −134.04 |
| HPV/p16Ki67-5y | −22.9% | −25.8% | +15.10 | +1.57 | −0.81 | +8.55 |
| HPV/p16Ki67-10y | −11.9% | −17.0% | +14.93 | −129.7 | −5.87 | −120.63 |
| p16Ki67/p16Ki67 | −24.3% | −24.4% | +19.57 | +233.30 | −6.87 | +246.00 |
*Reference for other scenarios. Cumulated incidence and mortality for 10 000 women eligible for OS on a lifetime horizon.
CC, cervical cancer; HPV, human papillomavirus; IndScr, individual screening; OS, organised screening; Pap, Papanicolaou.